TABLE 1

Biodistribution of 99mTc-Radiolabeled UA20 (at 1 and 3 Hours After Injection) and Control N3M2 scFvs (at 3 Hours After Injection) in Nude Mice Bearing Prostate Tumor Xenografts (n = 4)

UA20
Site1 h3 hN3M2UA20 blocking
Tumor3.71 ± 0.234.40 ± 0.350.26 ± 0.111.40 ± 0.50
Liver13.2 ± 1.142.74 ± 0.2413.8 ± 1.652.50 ± 0.40
Heart0.36 ± 0.080.13 ± 0.060.64 ± 0.130.20 ± 0.07
Kidneys100 ± 9.4281.4 ± 7.8981.5 ± 8.23101 ± 15.6
Lung1.51 ± 0.170.57 ± 0.121.38 ± 0.211.21 ± 0.32
Spleen5.44 ± 0.470.84 ± 0.116.68 ± 0.070.53 ± 0.32
Stomach0.14 ± 0.020.64 ± 0.220.56 ± 0.190.81 ± 0.04
Small intestine0.65 ± 0.070.80 ± 0.161.15 ± 0.280.54 ± 0.11
Large intestine1.48 ± 0.230.81 ± 0.311.03 ± 0.250.63 ± 0.34
Muscle0.13 ± 0.020.06 ± 0.010.35 ± 0.120.10 ± 0.04
Fat0.11 ± 0.010.07 ± 0.010.23 ± 0.080.42 ± 0.30
Blood0.68 ± 0.220.37 ± 0.141.97 ± 0.360.57 ± 0.24
  • Additional control (cold UA20 blocking) was also performed with 10-fold excess of cold UA20 scFv injected 1 h before injection of 99mTc-radiolabeled UA20. Biodistribution of 99mTc-radiolabeled UA20 at 3 h after injection was shown for this control experiment (UA20 blocking). Data are %ID/g ± SD.